Biovail Corp. posted a 37.1-per-cent jump in first-quarter profits to US$93.8 million or 58 cents a share, despite a slight drop in sales of its best-selling depression treatment Wellbutrin XL as other companies won the right to market generic versions of the drug.
From: www.ottawabusinessjournal.com
Biovail posts 37% jump in Q1 profits on stronger Ultram sales
Posted by Ruslan Abuzant at 9:43 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment